1338705-64-8

Basic information

• Product Name: 2-chloro-N'-(2-chloroacetyl)-3,4-bis((4-methoxybenzyl)oxy)benzohydrazide
• Synonyms: 2-chloro-N'-(2-chloroacetyl)-3,4-bis((4-methoxybenzyl)oxy)benzohydrazide
• CAS NO: 1338705-64-8
• Molecular Weight: 519.381
• Mol File: 1338705-64-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-chloro-N'-(2-chloroacetyl)-3,4-bis((4-methoxybenzyl)oxy)benzohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N'-(2-chloroacetyl)-3,4-bis((4-methoxybenzyl)oxy)benzohydrazide(1338705-64-8)
• EPA Substance Registry System: 2-chloro-N'-(2-chloroacetyl)-3,4-bis((4-methoxybenzyl)oxy)benzohydrazide(1338705-64-8)

Safety Data

• Hazardous Substances Data: 1338705-64-8(Hazardous Substances Data)

Upstream product

• 52009-53-7 2-chloro-3,4-dimethoxy-benzoic acid 
• 5417-17-4 2-chloro-3,4-dimethoxybenzaldehyde 
• 1338705-74-0 C₂₄H₂₃ClO₆ 
• 1338705-63-7 2-chloro-3,4-bis((4-methoxybenzyl)oxy)benzohydrazide 
• 79-04-9 chloroacetyl chloride 
• 1338705-62-6 C₂₇H₂₄ClNO₈ 

Downstream Products

• 1338705-65-9 2-(2-chloro-3,4-bis((4-methoxybenzyl)oxy)phenyl)-5-(chloromethyl)-1,3,4-oxadiazole 
• 1338705-66-0 2-(2-chloro-3,4-bis((4-methoxybenzyl)oxy)phenyl)-5-(pyrrolidin-1-ylmethyl)-1,3,4-oxadiazole 

Relevant articles and documents

Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship

The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection.